

## Change Notification for the UK Blood Transfusion Services

**Date of Issue:** 07 August 2025

**Implementation:** to be determined by each Service

No. 25 – 2025

**Component specifications:**


**Red Cells and Plasma, Leucocyte Deleted**

and

**Whole Blood, Leucocyte Deleted**


This notification includes the following changes:

	BM-DSG Bone Marrow & Peripheral Blood Stem Cell	CB-DSG Cord Blood	GDRI Geographical Disease Risk Index	TD-DSG Tissue – Deceased Donors	TL-DSG Tissue – Live Donors	WB-DSG Whole Blood & Components	Red Book Guidelines for the BTS in the UK
1. Red Cells and Plasma, LD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
2. Whole Blood, LD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>



**Ryan Evans**

Chair, Standing Advisory Committee  
on Blood Components (SACBC)



**Dr Stephen Thomas**

Professional Director of JPAC

Changes are indicated using the key below. This formatting will not appear in the final entry.

original text	«inserted text»	<del>deleted text</del>
---------------	-----------------	-------------------------

## 1. Changes apply to the **Red Book**

The following specification will be moved from **Annexe 3: Provisional Components**  
to

## **Chapter 7: Specifications for blood components**

### **7.2: Whole Blood Components**

Whole blood components are collected from UK donors as described in Chapter 5. These components undergo primary processing to separate the blood constituents into red cell, platelet, granulocyte and plasma components.

«Whole blood components are used to treat major haemorrhage providing a balanced transfusion of red cells and plasma in a single component.»

~~Currently in the UK whole blood components are not routinely used for transfusion, although provisional component specifications for use in clinical trials are described in Annexe 3.~~

#### **«7.2.1» A3.5: Red Cells and Plasma, Leucocyte Depleted**

A unit of blood collected into CPD anticoagulant, containing less than  $1 \times 10^6$  leucocytes.

##### **«7.2.1.1» A3.5.1: Technical information**

- Red Cells and Plasma, Leucocyte Depleted (LD) is intended for the treatment of major ~~traumatic~~ haemorrhage ~~with transfusion of a~~ «A» maximum of 4 units (or weight-related equivalent for children) «should be transfused for non-group O patients,» prior to switching to standard component therapy.
- A unit of whole blood collected in the UK currently consists of 470 mL  $\pm 10\%$  of blood from a suitable donor (see Chapter 3), plus 63 mL of CPD anticoagulant, which is then LD, and stored in an approved container. The Eurobloodpack contains 66.5 mL of anticoagulant and is suitable for the collection of 475 mL  $\pm 10\%$ , although in the UK a volume of 495 mL will not be exceeded.
- Donations of whole blood where the bleed time exceeded 15 minutes are not suitable for direct clinical use.
- Donations should be selected from male donors as a TRALI risk reduction measure.
- The component should be made from group O RhD negative «and positive», ~~Ke~~ negative donations.
- The component should be free from clinically significant irregular blood group antibodies including high-titre anti-A and anti-B.
- Red Cells and Plasma, LD, should be administered through a CE/UKCA/UKNI marked transfusion set.

### «7.2.1.2» ~~A3.5.2~~: Labelling

For general guidelines, see section 6.6.

The following shall be included on the label:

(\* = in eye-readable and UKBTS approved barcode format)

- Red Cells and Plasma, Leucocyte Depleted\* and volume
- the blood component producer's name\*
- the donation number\*
- the ABO group\*
- the RhD group stated as positive or negative\*
- the name, composition and volume of the anticoagulant solution
- the date of collection
- the expiry date\*
- the temperature of storage
- the blood pack lot number.\*

In addition, the following statements should be made:

#### **INSTRUCTION**

*Always check patient/component compatibility/identity*

*Inspect pack and contents for signs of deterioration or damage*

*Risk of adverse reaction/infection, including vCJD*

### «7.2.1.3» ~~A3.5.3~~: Storage

For general guidelines, see section 6.7.

- The component may be stored for a maximum of «21» ~~14~~ days at a core temperature of  $4 \pm 2^{\circ}\text{C}$ .
- Variation from the core temperature of  $4 \pm 2^{\circ}\text{C}$  must be kept to a minimum during storage and restricted to any short period necessary for examining, labelling or issuing the component.
- Exceptionally, i.e. due to equipment failure at a Blood Centre, red cell components which have been exposed to a core temperature not exceeding  $10^{\circ}\text{C}$  and not less than  $1^{\circ}\text{C}$  may be released for transfusion provided that:
  - the component has been exposed to such a temperature change on one occasion only
  - the duration of the temperature excursion has not exceeded 5 hours
  - a documented system is available in each Blood Centre to cover such eventualities
  - adequate records of the incident are compiled and retained.

### «7.2.1.4» ~~A3.5.4~~: Testing

In addition to the mandatory and other tests required for blood donations described in Chapter 9, and leucocyte counting (see sections 6.3 and 7.1.1), a minimum of 75% of those components tested for the parameters shown in Table «7.2.1» ~~A3.5~~ shall meet the specified values. Table «7.2.1» ~~A3.5~~ does not include plasma quality monitoring parameters as the Red Cells and Plasma, Leucocyte Depleted component will not be within the Blood Service at the end of shelf-life and as plasma quality at the point of production is already monitored as part of the process of manufacturing Fresh Frozen Plasma, Leucocyte Depleted from whole blood, using the same filtration process.

**Table «7.2.1» A3.5. Red Cells and Plasma, Leucocyte Depleted – additional tests**

Parameter	Frequency of test	Specification
Volume <sup>1</sup>	1% or as determined by statistical process control (if ≤10 components produced per month then test every available component)	470 ±50 mL
Haemoglobin content		≥40 g/unit
Haemolysis «2»	As per section 7.1.3	<0.8% of red cell mass
Leucocyte count «3» <sup>2</sup>	As per sections 6.3 and 7.1.1	<1 × 10 <sup>6</sup> /unit
<sup>1</sup> After volume losses resulting from leucodepletion		
« <sup>2</sup> This will require destructive testing and therefore any ABO group can be used for this assessment if units are not to be used clinically.»		
«3» <sup>2</sup> Methods validated for counting low numbers of leucocytes must be used		

#### «7.2.1.5» A3.5.5: Transportation

For general guidelines, see section 6.11.

For red cell components, transit containers, packing materials and procedures should have been validated to ensure the component surface temperature can be maintained between 2°C and 10°C during transportation. Additionally:

- the validation exercise should be repeated periodically
- if melting ice is used, it should not come into direct contact with the components
- dead air space in packaging containers should be minimised
- as far as is practicable, transit containers should be equilibrated to their storage temperature prior to filling with components
- transport time normally should not exceed 12 hours.

In some instances, it is necessary to issue red cell components that have not been cooled to their storage temperature prior to placing in the transit container. The transport temperature specified above is not applicable for such consignments.

#### «7.2.1.6» A3.5.6: Removal from and return to 2-6°C controlled storage within hospitals / pre-hospital clinical environment

For occasions when Red Cells and Plasma, Leucocyte Depleted are removed from 2-6°C controlled storage (e.g. when issued to a clinical area immediately prior to transfusion) and returned then:

- the time out of a controlled temperature environment should be restricted to under 30 minutes and on one occasion only.

Transfusion should be completed within 4 hours of issue out of a controlled temperature environment.

## 2. Changes apply to the **Red Book**

The following specification will be moved from **Chapter 7.2: Whole Blood Components** to

### **Annexe 4: Redundant Components**

#### «A4.6» ~~7.2.1~~: Whole Blood, Leucocyte Depleted

A unit of blood collected into an anticoagulant, containing less than  $1 \times 10^6$  leucocytes.

##### «A4.6.1» ~~7.2.1.1~~: Technical information

A unit of whole blood is collected in the UK from a suitable donor (see Chapters 3 and 5). The International Blood Pack specification contains 66.5 mL of anticoagulant and is suitable for the collection of 475 mL  $\pm 10\%$ .

Whole Blood, Leucocyte Depleted should be administered through a CE/UKCA/UKNI marked transfusion set.

##### «A4.6.2» ~~7.2.1.2~~: Labelling

For general guidelines, see section 6.6.

The following shall be included on the label:

(\* = in eye-readable and UKBTS approved barcode format)

- Whole Blood, Leucocyte Depleted\* and volume
- the blood component producer's name\*
- the donation number\*
- the ABO group\*
- the RhD group stated as positive or negative\*
- the name, composition and volume of the anticoagulant solution
- the date of collection
- the expiry date\*
- the temperature of storage
- the blood pack lot number.\*

In addition, the following statements should be made:

#### **INSTRUCTION**

*Always check patient/component compatibility/identity*

*Inspect pack and contents for signs of deterioration or damage*

*Risk of adverse reaction/infection, including vCJD*

### «A4.6.3» 7.2.1.3: Storage

For general guidelines, see section 6.7.

- The component may be stored for a maximum of 35 days at a core temperature of  $4 \pm 2^{\circ}\text{C}$  if an adenine-supplemented anticoagulant is used, otherwise the maximum period of storage is 28 days at a core temperature of  $4 \pm 2^{\circ}\text{C}$ .
- Variation from the core temperature of  $4 \pm 2^{\circ}\text{C}$  must be kept to a minimum during storage and restricted to any short period necessary for examining, labelling or issuing the component.
- Exceptionally, i.e. due to equipment failure at a Blood Centre, red cell components which have been exposed to a core temperature not exceeding  $10^{\circ}\text{C}$  and not less than  $1^{\circ}\text{C}$  may be released for transfusion provided that:
  - the component has been exposed to such a temperature change on one occasion only
  - the duration of the temperature excursion has not exceeded 5 hours
  - a documented system is available in each Blood Centre to cover such eventualities
  - adequate records of the incident are compiled and retained.

### «A4.6.4» 7.2.1.4: Testing

In addition to the mandatory and other tests required for blood donations described in Chapter 9, and leucocyte counting (see sections 6.3 and 7.1.1), a minimum of 75% of those components tested for the parameters shown in Table «A4.6» 7.2.1 shall meet the specified values.

**Table «A4.6» 7.2.1. Whole Blood, Leucocyte Depleted – additional tests**

Parameter	Frequency of test	Specification
Volume <sup>1</sup>	1% or as determined by statistical process control (if $\leq 10$ components produced per month then test every available component)	475 mL $\pm 10\%$
Haemolysis	As per section 7.1.3	$<0.8\%$ of red cell mass
Haemoglobin content	1% or as determined by statistical process control (if $\leq 10$ components produced per month then test every available component)	$\geq 40$ g/unit
Leucocyte count <sup>2</sup>	As per sections 6.3 and 7.1.1	$<1 \times 10^6/\text{unit}$
<sup>1</sup> After volume losses resulting from leucodepletion		
<sup>2</sup> Methods validated for counting low numbers of leucocytes must be used		

### «A4.6.5» 7.2.1.5: Transportation

For general guidelines, see section 6.11.

For red cell components, transit containers, packing materials and procedures should have been validated to ensure the component surface temperature can be maintained between  $2^{\circ}\text{C}$  and  $10^{\circ}\text{C}$  during transportation. Additionally:

- the validation exercise should be repeated periodically

- if melting ice is used, it should not come into direct contact with the components
- dead air space in packaging containers should be minimised
- as far as is practicable, transit containers should be equilibrated to their storage temperature prior to filling with components
- transport time normally should not exceed 12 hours.

In some instances, it is necessary to issue red cell components that have not been cooled to their storage temperature prior to placing in the transit container. The transport temperature specified above is not applicable for such consignments.